Multimodal Imaging Market

Multimodal Imaging Market Size, Market Forecast and Outlook by Fact.MR

• The multimodal imaging market was valued at USD 3.1 billion in 2025.
• Demand is set to reach USD 3.2 billion in 2026 at a CAGR of 4.7% during the forecast period.
• Sustained clinical and research adoption takes the valuation to USD 5.1 billion through 2036 as hospitals and diagnostic centers invest in hybrid systems for oncology, neurology, cardiology, and ophthalmology.

Summary of Multimodal Imaging Market

• Market Definition
  • Multimodal imaging combines two or more imaging methods to improve disease visualization, staging, diagnosis, and treatment monitoring. Scope is defined by hybrid hardware, imaging software, contrast or tracer use, clinical application, and the ability to combine functional and anatomical information.
• Demand Drivers in the Market
  • Nuclear medicine physicians need imaging for metabolic and anatomical assessment.
  • Oncology imaging heads require accurate tumor staging and treatment response monitoring.
  • Diagnostic centers need faster workflows and clearer image interpretation support.
• Key Segments Analyzed
  • PET/CT Systems: PET/CT systems are expected to account for 31.0% share in 2026 because oncology and cardiology rely on combined metabolic and anatomical imaging.
  • Equipment: Equipment is projected to hold 58.0% share in 2026 as scanners and hybrid systems carry the highest capital value.
  • Oncology: Oncology is estimated to capture 36.0% share in 2026 due to tumor staging, recurrence detection, and treatment monitoring.
  • Hospitals: Hospitals are likely to hold 49.0% share in 2026 because hybrid imaging requires infrastructure, specialists, and patient referral volume.
  • Direct Institutional Sales: Direct institutional sales are projected to account for 51.0% share in 2026 because buyers need installation, training, and service support.
  • Geography: China is forecast to grow at 5.8% CAGR through 2036, supported by hospital modernization and domestic imaging system development.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Senior Analyst at Fact.MR, opines, “Multimodal imaging growth will depend on clinical integration. Hospitals are not buying hybrid scanners only for image quality. They want systems that improve staging, guide therapy planning, and support faster interpretation. Suppliers will gain where they combine hardware performance, software depth, radiology workflow support, and service reliability.”
• Strategic Implications
  • Hospitals must evaluate multimodal imaging through clinical pathway value and not scanner specifications alone.
  • Imaging companies should strengthen software and AI interpretation tools to protect system differentiation.
  • Diagnostic centers need utilization planning because hybrid imaging systems require high procedure volume.
• Methodology
  • Fact.MR interviews radiology department heads, nuclear medicine physicians, diagnostic imaging center operators, imaging equipment distributors, and hospital buyers.
  • Research reviews device approvals, company disclosures, product portfolios, clinical imaging guidance, and hospital infrastructure signals.
  • Estimates use scanner installations, replacement demand, hybrid imaging adoption, procedure volume, software use, and regional capital investment.
  • Forecasts are validated through supplier checks, buyer interviews, procedure-flow review, regulatory database checks, and regional imaging infrastructure analysis.

Radiology leaders are being pushed to decide between single-modality imaging and hybrid platforms that combine anatomical and functional information. This shift is visible in PET/CT, SPECT/CT, PET/MR, and OCT/fundus systems. FDA documentation for Siemens Biograph systems describes them as combined X-ray CT and PET scanners, supporting the clinical role of hybrid PET/CT systems. [1] A practical point often missed is that multimodal imaging value depends on interpretation workflow, not only scanner quality. Hospitals need trained readers, image fusion software, and reporting integration.

The main inflection point arrives when multimodal imaging becomes part of disease pathway planning rather than a premium scan option. Hospitals trigger this shift by linking hybrid imaging with tumor staging, cardiac assessment, neuroimaging, and treatment monitoring. Once this happens, multimodal imaging moves from isolated capital equipment to a diagnostic decision platform.

China is projected to record 5.8% CAGR through 2036 as healthcare infrastructure and domestic imaging production expand. The United States is likely to grow at 4.9% CAGR through advanced imaging adoption and AI-supported interpretation. India is forecast to post 4.8% CAGR as diagnostic imaging access and oncology care expand. Germany is projected to grow at 4.5% CAGR, Japan at 4.2% CAGR, the UK at 4.0% CAGR, and Brazil at 3.8% CAGR. Country variation depends on imaging reimbursement, specialist availability, hospital capital budgets, and radiotracer access.

Segmental Analysis

Multimodal Imaging Market Analysis by Technology

PET/CT systems are projected to hold 31.0% share in 2026 as oncology, cardiology, and neurology use metabolic and anatomical data together. These systems help clinicians localize abnormal tracer uptake and link it with CT-based anatomy. SPECT/CT systems remain important in cardiac and bone imaging workflows. PET/MR systems are gaining demand where soft tissue contrast and reduced radiation exposure matter. OCT/fundus systems support ophthalmology by combining retinal structure and fundus views. Other hybrid systems serve research and specialized imaging needs. Siemens states that Biograph Vision Quadra PET/CT has an extended axial field of view and time-of-flight performance for advanced PET/CT imaging. [2]

• Clinical Fusion: PET/CT combines metabolic activity with anatomical localization.
• Cardiac Support: SPECT/CT remains important for cardiovascular and bone assessment.
• Soft Tissue Need: PET/MR supports oncology and neurology where MRI contrast adds value.

Multimodal Imaging Market Analysis by Product

Equipment is projected to account for 58.0% share in 2026 because hybrid scanners, imaging towers, detectors, and gantry systems form the largest purchase value. Hospitals and imaging centers need capital equipment before software and reagents can generate recurring workflow value. Reagents remain important in PET and SPECT imaging because tracer access determines scan availability. Software is gaining faster adoption as AI, image fusion, and workflow automation improve interpretation speed. Fact.MR analysis suggests that equipment leads because multimodal imaging still depends on installed system capacity. GE HealthCare’s Omni Legend is described as a PET/CT system intended for qualified healthcare professionals for imaging positron-emitting radiopharmaceutical distribution and localization. [3]

• Capital Base: Equipment carries the highest value in multimodal imaging installations.
• Tracer Dependence: Reagents support PET and SPECT scan availability.
• Workflow Value: Software improves image fusion, interpretation, and reporting efficiency.

Multimodal Imaging Market Analysis by Application

Oncology is predicted to reach 36.0% share in over the assessment period because cancer care depends on accurate staging, recurrence detection, therapy planning, and treatment response assessment. PET/CT and PET/MR help clinicians combine anatomical findings with molecular or metabolic activity. Brain and neurology applications are expanding through PET/MR and advanced hybrid imaging in neurodegenerative diseases and brain tumors. Cardiology uses SPECT/CT and PET/CT for perfusion and functional assessment. Ophthalmology uses OCT/fundus systems for retinal diseases. Other applications include infection, inflammation, and preclinical research. Siemens Healthineers introduced Biograph One PET/MR as a system designed to visualize organ location, function, and cellular metabolism together. [4]

• Tumor Staging: Oncology uses hybrid imaging to connect lesion location with metabolic activity.
• Neurology Use: PET/MR supports brain imaging where soft tissue contrast matters.
• Cardiac Assessment: SPECT/CT and PET/CT support perfusion and functional evaluation.

Multimodal Imaging Market Analysis by End User

Hospitals are likely to hold 49.0% share in 2026 because multimodal imaging requires infrastructure, specialist staffing, radiotracer logistics, and integrated patient referral systems. Large hospitals use hybrid imaging for oncology, cardiology, neurology, and complex diagnostic cases. Diagnostic imaging centers are gaining share because outpatient imaging demand continues to rise. Academic and research institutes use multimodal systems for preclinical and translational studies. Specialty clinics use OCT/fundus and selected hybrid platforms where procedure volume supports investment. End-user adoption depends on procedure throughput, reimbursement, and trained imaging staff. Philips’ annual reporting reflects its Diagnosis & Treatment business exposure, which includes imaging and image-guided therapy activities. [5]

• Hospital Depth: Hospitals have the infrastructure needed for hybrid imaging systems.
• Outpatient Growth: Diagnostic imaging centers use multimodal systems for referral-based procedures.
• Research Role: Academic institutes use hybrid imaging for translational and preclinical work.

Multimodal Imaging Market Analysis by Sales Channel

Direct institutional sales are projected to account for 51.0% share in 2026 because multimodal imaging systems require planning, installation, training, service, and software integration. Large hospitals and imaging networks often buy directly from equipment manufacturers. Medical device distributors remain important in emerging markets and smaller diagnostic centers. Tender-based sales serve public hospitals and government-backed imaging programs. Integrated imaging solution providers support buyers that need scanners, software, maintenance, and workflow tools bundled together. Channel choice affects installation quality and long-term service uptime. Siemens Healthineers’ reporting highlights imaging as a core business area, reinforcing the role of direct supplier relationships in large imaging purchases. [6]

• Installation Support: Direct sales help buyers manage system planning and service needs.
• Regional Access: Distributors support smaller imaging centers and developing markets.
• Tender Buying: Public hospitals often purchase imaging systems through formal procurement.

Multimodal Imaging Market Drivers, Restraints, and Opportunities

Cancer, cardiovascular disease, and neurological disorders are the main demand anchors for multimodal imaging. Hybrid systems help clinicians combine anatomy, physiology, and metabolic activity in one diagnostic pathway. FDA 510(k) documentation for PET/CT systems reinforces how these systems are positioned for whole-body and organ-specific imaging use. AI-supported analysis and cloud-based imaging workflows are creating new value in interpretation and reporting. These factors support demand for hardware and software that improve diagnostic confidence.

High equipment cost remains the main restraint. PET/MR and advanced PET/CT systems require large capital budgets, shielding, site planning, tracer access, trained staff, and maintenance contracts. Reimbursement gaps can slow adoption in emerging markets. Radiotracer availability can limit PET procedure growth even where scanners are installed. The IAEA notes that nuclear medicine uses radioactive materials to diagnose and treat disease, which makes infrastructure and safety practices important for adoption. [7] Suppliers that cannot support installation, training, and uptime may struggle to convert interested buyers.

Opportunities in the Multimodal Imaging Market

• AI Imaging Software: Suppliers can expand through image fusion, reconstruction, and interpretation support.
• PET/MR Adoption: Hospitals can use PET/MR where soft tissue contrast and functional imaging both matter.
• Outpatient Imaging: Diagnostic centers can grow through high-throughput multimodal imaging services.

Regional Analysis

Based on the regional analysis, the multimodal imaging market is segmented into North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa across 40 plus countries.

Source: Fact.MR analysis, based on proprietary forecasting model and primary research

East Asia Multimodal Imaging Market Analysis

East Asia shows steady growth because hospitals are investing in advanced diagnosis, oncology imaging, and domestic imaging technology. China creates the strongest regional growth opportunity through hospital modernization and rising local production. Japan has a mature imaging base where replacement and advanced clinical applications support demand. Fact.MR analysis indicates that buyers in this region evaluate systems through image quality, service uptime, and software support. Radiotracer access and specialist training remain important adoption factors.

• China: China is projected to record 5.8% CAGR from 2026 to 2036 as healthcare infrastructure and domestic imaging production expand. Large hospitals need PET/CT, SPECT/CT, and AI-supported imaging tools for oncology and neurology. Domestic manufacturers are improving availability, but premium systems still depend on clinical proof and service quality. Suppliers with strong installation and software support can improve adoption.
• Japan: Japan is projected to grow at 4.2% CAGR through 2036. Advanced hospitals use multimodal imaging for oncology, neurology, cardiology, and research workflows. Aging demographics support demand for accurate diagnostic imaging. Buyers value precision, service continuity, and proven image quality. Suppliers gain where they support integrated workflows and trained reader adoption.

North America Multimodal Imaging Market Analysis

North America remains a major demand base because hospitals and imaging networks use advanced hybrid systems across oncology, cardiology, and neurology. The United States leads regional demand through established imaging infrastructure and strong adoption of AI-supported interpretation tools. FDA clearance pathways support regulated product introduction. Fact.MR analysis suggests that buyers in this region value clinical evidence, uptime, software integration, and service contracts. PET/CT and SPECT/CT remain central to multimodal imaging adoption.

• United States: The United States is likely to grow at 4.9% CAGR through 2036 as advanced imaging adoption and AI-supported interpretation expand. Hospitals use PET/CT and SPECT/CT for oncology, cardiology, and neurology workflows. Imaging centers invest where scan volume supports capital equipment cost. FDA-cleared systems and strong service contracts influence buyer confidence. Suppliers with software depth can defend premium accounts.

South Asia and Pacific Multimodal Imaging Market Analysis

South Asia and Pacific is gaining momentum as healthcare infrastructure and oncology diagnosis capacity expand. India is the key growth country because large hospitals and diagnostic chains are investing in advanced imaging. Fact.MR analysis suggests that adoption in this region depends on capital budgets, radiotracer access, and trained specialists. Diagnostic imaging centers can grow faster where urban referral networks create scan volume. Cost remains a constraint for PET/MR and advanced hybrid systems.

• India: India is forecast to post 4.8% CAGR through 2036 as diagnostic imaging access and oncology care expand. Private hospitals and diagnostic chains are increasing investment in PET/CT and advanced imaging workflows. Public-sector installations can improve access in selected cities. Skilled readers and radiotracer supply remain central to adoption. Suppliers with financing support and service coverage can improve market penetration.

Western Europe Multimodal Imaging Market Analysis

Western Europe demand is shaped by hospital renewal, cancer diagnosis programs, and strong research use. Germany and the UK are key countries in this regional spread. Buyers often evaluate imaging systems through clinical evidence, reimbursement, radiation management, and service reliability. Fact.MR analysis indicates that PET/MR and AI-supported software can grow where hospitals have specialist pathways and research programs. Growth is moderate because imaging infrastructure is already well developed.

• Germany: Germany is projected to grow at 4.5% CAGR during 2026 to 2036. Hospitals use multimodal imaging across oncology, neurology, and cardiology. Strong research centers support adoption of advanced PET/MR and software tools. Buyers value clinical proof and technical service support. Replacement demand remains important because many facilities already use advanced imaging systems.
• U.K.: The UK market is supported by oncology diagnostics demand and ongoing hospital imaging upgrades, which drive system adoption across diagnostic imaging centers and hospital networks. These facilities require solutions that improve throughput and reporting accuracy while aligning with clinical workflow needs. The UK is expected to expand at 4.0% CAGR over the study period. Public-sector budgeting can influence replacement cycles, making service support and integrated workflow software important differentiators for suppliers seeking preference.

Latin America Multimodal Imaging Market Analysis

Latin America demand is supported by oncology imaging needs, private hospital investment, and gradual expansion of diagnostic infrastructure. Brazil leads regional demand because it has the largest healthcare and imaging base. Fact.MR analysis indicates that adoption remains concentrated in private hospitals and major diagnostic centers. Cost, service access, and radiotracer availability limit wider diffusion. Suppliers need strong distributor partnerships and local service teams.

• Brazil: Brazil is projected to record 3.8% CAGR from 2026 to 2036. Oncology imaging and private diagnostic centers support multimodal imaging demand. PET/CT adoption is stronger in major cities with specialist capacity. Equipment cost and service availability affect expansion outside large urban markets. Suppliers with local partners and financing support can build repeat demand.

Competitive Aligners for Market Players

The multimodal imaging market is concentrated around global imaging companies, nuclear medicine system suppliers, ophthalmic imaging firms, and specialized preclinical imaging providers. Siemens Healthineers, GE HealthCare, Philips, Canon, United Imaging, Bruker, Mediso, Topcon, and Carl Zeiss compete through system performance, software integration, service reach, and application depth. Large suppliers benefit from installed base and hospital relationships.

Competitive advantage depends on hybrid hardware and software workflow. Siemens Healthineers’ Biograph Vision Quadra PET/CT clearance and Biograph One PET/MR announcement show continued investment in hybrid imaging platforms. GE HealthCare’s Omni Legend PET/CT documentation supports its role in PET/CT system development. These systems show why PET/CT and PET/MR remain central to competitive positioning.

Software and AI support are becoming stronger differentiators. Philips’ annual reporting and Siemens Healthineers’ imaging focus show how large suppliers connect imaging systems with digital workflows. Bruker’s preclinical imaging portfolio and annual reporting support its role in research-focused multimodal imaging systems. Companies that combine hardware, software, service uptime, and clinical training are better placed through 2036.

Key Players in Multimodal Imaging Market

• Siemens Healthineers
• GE HealthCare
• Koninklijke Philips N.V.
• Canon Inc.
• Shanghai United Imaging Healthcare Co. Ltd.
• Bruker Corporation
• Spectrum Dynamics Medical Inc.
• Nipro Corporation
• PerkinElmer Inc.
• Mediso Ltd.
• Carl Zeiss AG
• MILabs B.V.
• MR Solutions Ltd.
• Neusoft Medical Systems Co. Ltd.
• Topcon Corporation
• TriFoil Imaging

Bibliography

• [1]. U.S. Food and Drug Administration. (2025, July 3). K251671: Biograph Vision PET/CT systems. U.S. Food and Drug Administration.
• [2]. Siemens Healthineers. (2021, March 8). Siemens Healthineers announces FDA clearance of Biograph Vision Quadra. Siemens Healthineers.
• [3]. U.S. Food and Drug Administration. (2024, August 8). K241665: GE Omni Legend PET/CT system. U.S. Food and Drug Administration.
• [4]. Siemens Healthineers. (2024, December 1). Siemens Healthineers plans to support new paths for personalized cancer care with Biograph One. Siemens Healthineers.
• [5]. Philips. (2025, February 21). Annual Report 2024. Philips.
• [6]. Siemens Healthineers. (2024, November 26). Annual Report 2024. Siemens Healthineers.
• [7]. International Atomic Energy Agency. (2026). Nuclear medicine and diagnostic imaging resources. International Atomic Energy Agency.

This Report Addresses

• Strategic intelligence on multimodal imaging demand across PET/CT, SPECT/CT, PET/MR, OCT/fundus systems, software, and reagents globally.
• Market forecast from USD 3.2 billion in 2026 to USD 5.1 billion by 2036 at a CAGR of 4.7%.
• Growth opportunity mapping across China healthcare modernization, United States advanced imaging adoption, India diagnostic infrastructure, Germany research hospitals, and Japan replacement demand.
• Segment analysis by technology, product, application, end user, and sales channel.
• Regional outlook covering East Asia imaging investment, North America advanced hybrid systems, South Asia diagnostic expansion, Western Europe research-linked adoption, and Latin America private imaging demand.
• Competitive analysis of Siemens Healthineers, GE HealthCare, Philips, Canon, United Imaging, Bruker, Mediso, Carl Zeiss, Topcon, and MILabs.
• Product assessment covering PET/CT systems, SPECT/CT systems, PET/MR systems, OCT/fundus systems, AI imaging software, and image fusion tools.
• Report delivered through PDF, Excel datasets, and presentation formats, supported by primary interviews, regulatory review, supplier portfolio checks, procedure-volume analysis, and hospital buyer validation.

Multimodal Imaging Market Definition

The multimodal imaging market covers systems, software, reagents, and related solutions that combine two or more imaging methods to generate complementary diagnostic information. The market includes PET/CT, SPECT/CT, PET/MR, OCT/fundus imaging, optical hybrid systems, and software used to fuse or analyze images from multiple modalities. It differs from single-modality imaging because it combines structural, functional, metabolic, or molecular data in one diagnostic workflow.

Multimodal Imaging Market Inclusions

The scope includes PET/CT systems, SPECT/CT systems, PET/MR systems, OCT/fundus systems, hybrid optical imaging platforms, image fusion software, AI-supported image analysis tools, radiopharmaceutical-linked imaging workflows, contrast agents, research imaging platforms, and related accessories. Products used in hospitals, diagnostic imaging centers, academic research, oncology, neurology, cardiology, and ophthalmology are included when the workflow combines multiple imaging modalities.

Multimodal Imaging Market Exclusions

The scope excludes standalone MRI, standalone CT, standalone ultrasound, standalone X-ray, pure PACS software without multimodal analysis, general radiology equipment without hybrid imaging capability, and non-medical imaging systems. Radiotherapy equipment is excluded unless used with integrated multimodal imaging for diagnosis or treatment planning. General laboratory imaging systems are excluded unless they support multimodal biomedical imaging.

Multimodal Imaging Market Research Methodology

• Primary Research:Interviews with radiologists, nuclear medicine physicians, hospital imaging heads, diagnostic center owners, oncology imaging specialists, and medical imaging distributors.
• Desk Research:Review of FDA device clearances, company annual reports, imaging system product pages, nuclear medicine guidance, hospital imaging investment signals, and clinical imaging documentation.
• Market-Sizing and Forecasting:Forecasting uses installed imaging base, hybrid system adoption, replacement cycles, radiotracer availability, hospital capital spending, and diagnostic procedure growth.
• Data Validation and Update Cycle:Forecasts are validated through device supplier checks, imaging center interviews, hospital buyer inputs, regulatory review, and regional diagnostic infrastructure analysis.